Introduction
============

Clinical diagnosis of most cancers and their precursors is predominantly based on phenotypic markers such as appearance of cell nuclei. Classification and staging of disease is determined by evaluation of gross structural features, such as extent of local tumour invasion and presence of disease in other organs. It is now established that cancer arises as a result of successive genetic changes altering cellular processes including growth, angiogenesis, senescence, and apoptosis ([@b49-bmi-2007-447]). Additionally, many cancers appear to have active inflammation and wound healing mechanisms ([@b18-bmi-2007-447]). Proteins taking part in these cellular mechanisms are often strong candidates for biomarkers and molecular targets.

Cervical cancer is usually the result of a human papillomavirus (HPV) infection which initiates neoplastic progression mainly through viral oncoproteins E6 and E7 within the cervical transformation zone at the squamous/columnar junction. The role of HPV to the pathogenesis of cervical cancer has been addressed in recent reviews (zur [@b166-bmi-2007-447]; [@b157-bmi-2007-447]). Many HPV types produce only productive lesions following infection and are not associated with human cancers. In such lesions, the expression of viral gene products is carefully regulated, with viral proteins being produced at defined times and at regulated levels as the infected cell migrates towards the epithelial surface. The events that lead to viral synthesis in the upper epithelial layers appear common to both the low- and high-risk HPV types. Virus-induced cancers most often arise at sites where productive infection cannot be suitably supported. Productive infection can be divided into distinct phases, with different viral proteins playing specific roles ([@b25-bmi-2007-447]). Upon infection, normal cells gradually advance through stages of cervical intraepithelial neoplasia (CIN). Mild dysplasia (CINI) presents as only a subset of the low third of the epithelium appearing dysplastic, moderate dysplasia (CINII) occurs where the dysplastic cells involve about one-half of the thickness of the epithelium of the cervix, and severe dysplasia (CINIII), or carcinoma-in-situ, is described as the condition where the entire thickness of the epithelium is disordered but the abnormal cells have not yet spread below the surface. If carcinoma-in-situ is not treated, it will often grow into an invasive cervical cancer. High grade dysplasia is considered the most advanced dysplasia with atypical changes in many of the cells and a very abnormal growth pattern of the glands; some of the glands are branching or budding. More than 50% of the cells have large, spotted nuclei and are frequently dividing while the cellular cytoplasm is reduced and looks abnormal. Cancer of the cervix was one of the most common causes of cancer death for American women, but between 1955 and 1992 the number of cervical cancer deaths in the United States dropped by 74% due to the introduction of the Pap test ([@b103-bmi-2007-447]). Death rates from cervical cancer continue to decline by nearly 4% per year. Even so, the American Cancer Society reports that in 2006, about 3,700 of the 9,710 women diagnosed with cervical cancer in the United States have died from this disease.

HPV infection causes changes in expression levels of a wide variety of genes ([@b162-bmi-2007-447]). These differences in gene expression between pre-invasive neoplastic and non-neoplastic tissue give clues to the molecular basis of cancer. Early detection of cervical cancer based on molecular characterization would be clinically advantageous; risk of neoplastic lesion progression could be predicted and response to therapy could be monitored in real time at a molecular level. To monitor molecular characterisation of cancer it follows that the ability to optically image in real-time the molecular features of cancer *in vivo* is critical ([@b45-bmi-2007-447]; [@b112-bmi-2007-447]; [@b154-bmi-2007-447]; [@b60-bmi-2007-447]; [@b74-bmi-2007-447]; [@b131-bmi-2007-447]; [@b20-bmi-2007-447]) and requires safe, molecular-specific contrast agents whose images can be monitored rapidly and non-invasively during their uptake and distribution. The analysis presented here evaluates serial analysis of gene expression (SAGE) libraries to identify novel, cell-surface gene products. Upon mapping of highly differentially expressed SAGE tags to their corresponding genes, the gene products are candidates for antibody testing and optical contrast agent development.

Contrast Agents and Optical Imaging
===================================

Short of prevention, improved early stage cancer diagnosis would provide the greatest benefit for cancer patients. Because proteins may regulate gene expression, ligand-binding properties, molecular structure and dynamics on a temporal basis, protein biomarkers have a significant impact in cancer detection and therapy as therapies are becoming targeted to specific signal transduction and metabolic pathways. For example, breast cancers respond to HERCEPTIN (trastuzumab) if the tumor over-expresses Her-2/neu ([@b9-bmi-2007-447]; [@b122-bmi-2007-447]). In the same way, GLEEVEC (imatinib) is most effective against cancers carrying the bcr-Abl translocation ([@b27-bmi-2007-447]) and targeted molecular cancer therapy is already used successfully for the eradication of acute leukaemia ([@b40-bmi-2007-447]; [@b161-bmi-2007-447]). These examples imply that it will be important to produce biomarkers for all stages of cancer. Reliable diagnostics such as DNA screening and immunocytochemical analysis of known cervical neoplasia biomarkers p16^INK4A^ and minichromosome maintenance (MCM) proteins are not implemented *in vivo*. Real-time biomarkers of the physiological state of the disease process or markers representative of treatment efficacy will bring immeasurable benefit to cancer care in terms of individualized agent selection and dosing. Furthermore, series of agents could be tested to determine empirically the localization of cancer and/or the most effective therapy.

Routine clinical cancer detection employs non-specific contrast agents such as acetic acid which enhance the nuclear backscattering but are limited by small signal magnitude. The field of molecular imaging is rapidly developing imaging agents with high affinity and specificity for targeted biomarkers. These new agents allow for the possibility of disease detection earlier than is currently feasible (Weissleder, 2001; [@b64-bmi-2007-447]). For example, cancer metastases missed by conventional anatomically based imaging methods may be detected in patients by molecular imaging ([@b54-bmi-2007-447]). Optical imaging of tissue can be carried out non-invasively in real time, giving high spatial resolution (\<1 μm lateral resolution). A number of optical techniques have been established including confocal microscopy ([@b154-bmi-2007-447]; Collier et al. 2005), multispectral fluorescence imaging ([@b3-bmi-2007-447]; [@b36-bmi-2007-447]), reflectance spectroscopy with polarised and unpolarised light ([@b134-bmi-2007-447], [@b135-bmi-2007-447]; [@b145-bmi-2007-447]), multispectral reflectance imaging with polarised and unpolarised light ([@b36-bmi-2007-447]; [@b46-bmi-2007-447]), and fluorescence spectroscopy ([@b44-bmi-2007-447]; [@b149-bmi-2007-447]; [@b113-bmi-2007-447]; [@b135-bmi-2007-447]). Together with emerging molecular tools (e.g. DNA screening, tissue proteomic and serum markers), biomarker imaging may soon be used for real-time screening, diagnosis, and detection of disease recurrence and progression ([@b124-bmi-2007-447]).

Contrast agents consist of a biomarker specific probe molecule, such as an antibody, conjugated to an optically suitable label. By topically applying molecular specific contrast agents to tissues, the scope of molecular changes that can be probed using optical imaging is significantly enhanced. Presently, contrast agents based on metal nanoparticles, organic fluorescent dyes, and quantum dots coupled to monoclonal antibodies against cancer specific biomarkers are being developed ([@b136-bmi-2007-447]; [@b111-bmi-2007-447]).

SAGE Libraries and Tag Mapping
==============================

The SAGE technique is capable of producing a molecular representation of cervical tissue based on expressed genes. SAGE is not dependent on pre-existing databases of expressed genes and so provides an independent view of gene expression profiles within the mRNA populations ([@b146-bmi-2007-447]). SAGE library construction is well documented in the literature ([@b147-bmi-2007-447] and [@b146-bmi-2007-447]; [@b87-bmi-2007-447]; [@b126-bmi-2007-447]; [@b105-bmi-2007-447]; [@b127-bmi-2007-447]). Several recent gene expression profiles of *in vitro* HPV-infected cultured keratinocytes and from cervical carcinoma clinical samples have proposed changes in gene expression induced by HPV and in early cervical carcinomas ([@b142-bmi-2007-447]; [@b125-bmi-2007-447]; [@b28-bmi-2007-447]; [@b104-bmi-2007-447]). Some studies have compared normal versus tumor-induced gene expression in cervical samples with the aim of identifying potential tumor markers of clinical value ([@b133-bmi-2007-447]; [@b19-bmi-2007-447]).

To identify genes expressed at dissimilar levels in preinvasive neoplastic and non-neoplastic untyped cervical tissue, we analysed sixteen long-SAGE libraries; 4 from normal cervical tissue samples, 3 of a mild dysplasia (CINI), 3 of moderate dysplasia (CINII), and 6 of severe dysplasia (CINIII), or carcinoma-in-situ. The CIN tissues are positive for MUC16. Raw numbers of longSAGE tags generated and library names are given in [Tables 1](#t1-bmi-2007-447){ref-type="table"} and [2](#t2-bmi-2007-447){ref-type="table"}. DiscoverySpace ([@b120-bmi-2007-447]), an in-house graphical software application backed by a relational database system designed to support SAGE gene expression analysis, was used to query data from over 25 publicly available data sources, as well as internal experimental results. Using DiscoverySpace, selected SAGE tag sequences were mapped to counterpart RefSeq ([@b107-bmi-2007-447], [@b108-bmi-2007-447]) genes and confirmed using SAGE tag co-ordinates to establish gene identity through Ensembl ([@b59-bmi-2007-447]; homo_sapiens\_ core_41_36c). Genes were manually curated (EntrezGene) to ascertain gene identity and gene product localisation. These cervical longSAGE libraries were created from the epithelium of cervical biopsy samples collected just prior to LEEP (Loop Electrosurgical Excision Procedure). Tissue samples were placed into RNAIater and frozen at −80 °C within 10 minutes of being excised from the patient. These longSAGE libraries ([@b132-bmi-2007-447]) have been submitted to the NCBI Gene Expression Omnibus (GEO) repository.

Any protein differentially expressed in cancer tissue, compared to normal tissue, or any protein known to be involved in cancer development, has potential as a candidate cancer biomarker. Genes presenting properties which identify them as likely targets for cancer diagnosis or prognosis must be separated from thousands of other genes which also may also possess clinical potential. Hundreds of potential candidates must be set aside in favour of gene products which offer the most promising characteristics. We focus on genes encoding membrane associated proteins because membrane-bound proteins are most likely to be accessible to topical application of contrast agents and have a rapid time frame for contrast agent visualization. Genes expressing the greatest number of tags combined with high levels of differential expression between dysplastic and normal tissue are the most likely to be observed by contrast agents *in vivo*.

For optical imaging of tumors by topical application *in vivo* of contrast agents to be of practical use, a large number of contrast agent receptors are required. One of the standard methods to detect candidate biomarkers is to identify genes with amplified expression in cancer and/or normal tissues. We compared transcription profiles and retained the most highly expressed membrane-bound gene products whose differential expression level is greater than two-fold. Many cell-surface proteins can potentially be developed as targets for optical contrast agents. Using longSAGE, we have also identified the most highly differentially expressed transcripts between disease and normal tissue. [Table 1](#t1-bmi-2007-447){ref-type="table"} specifies those genes (with cell-surface gene products) up-regulated in the CINI and CINIII stages of dysplasia and [Table 2](#t2-bmi-2007-447){ref-type="table"} lists genes up-regulated in normal tissue. Short descriptions of these protein biomarkers are given in the appendix and annotations of protein structural information, if available, are included. Given that CINII is difficult to determine clinically, it was not included in these comparisons. Contrast agent visualization of the epidermal growth factor receptor (EGFR) using an anti-EGFR monoclonal antibody has already been successful ([@b111-bmi-2007-447]). More of these markers should prove amenable to contrast agent development and topical formulations consisting of a range of contrast agents could help adjust to individual patient differences in gene expression.

Cervical Intraepithelial Neoplasia Stage Biomarkers
===================================================

It is possible to evaluate a marker for presence or absence, but to correlate a marker or array of markers to changes in cellular localization relative to other markers is probably the most interesting and beneficial in terms of dysplasia progression, environment, therapy selection, and follow-up. The known function of these genes grants some insight into the biology of cervical neoplasia. For instance, several of these cell surface markers are involved in transport and/or signaling. MUCX and CD74, upregulated in CINI and CINIII, have signaling gene products known to be associated with carcinomas. CD74 is also known to be a high affinity binding protein for macrophage migration-inhibitory factor (MIF) which is implicated in tumor cell growth and angiogenesis. TSPAN1, upregulated in CINIII almost 10-fold, also plays a role in cell motility and growth. See [Appendix](#app1-bmi-2007-447){ref-type="app"} for gene-specific references.

Our analysis of cervical cancer longSAGE expression profiles direct attention to some genes with relatively equal distribution in CINI and CINIII, such as PIGR. Another marker, ANPEP, is present at significantly different expression levels in CINI and CINIII. This knowledge expands the possibilities for rapid visualization between normal and stages of dysplasia *in vivo*. As discussed earlier, these cell surface targets were found by identifying differentially expressed genes. More often than not, a highly expressed tag is not localised to the cell surface and, for these purposes, does not warrant further attention. However, a highly differentially expressed gene whose gene product is not membrane-bound is sometimes found to be part of a mechanism which affects the cell surface and thereby the gene product becomes of potential use. TFF3 (trefoil factor 3), for instance, is up-regulated 13-fold in CINIII and 27-fold in CINI. Members of the trefoil family are characterised by having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulphides. They are stable, secretory proteins whose functions are not defined but may protect the mucosa from insults, stabilize the mucus layer and affect healing of the epithelium. VANGL1 (Van Gogh-like protein 1) is an integral membrane protein which is serine/threonine phosphorylated and translocated to cytoplasmic vesicles in response to TFF3 stimulation ([@b68-bmi-2007-447]). VANGL1 protein acts as a downstream effector of TFF3 signalling and regulates wound healing of intestinal epithelium. TFF3 is commonly expressed in hepatocellular carcinoma and its expression correlates with tumor grade ([@b70-bmi-2007-447]). TFF3 overexpression may be a critical process in mouse and human hepatocellular carcinogenesis ([@b101-bmi-2007-447]). The group of trefoil factor peptides (TFF1-3) are part of the protective mechanism operating in the intestinal mucosa and play a fundamental role in epithelial protection, repair, and restitution ([@b148-bmi-2007-447]). TFF3 and the essential tumor angiogenesis regulator VEGF exert potent pro-invasive activity through STAT3 signalling in human colorectal cancer cells ([@b119-bmi-2007-447]). That VANGL1 returned to cell membranes within 45 minutes of TFF3 stimulation ([@b68-bmi-2007-447]) could explain the low VANGL1 tag counts, 1--3 tags per library, observed in the longSAGE libraries.

Conclusions
===========

Molecular specific contrast agents may provide the ability to directly image the cancer process; but biomarker discovery can be a lengthy process as candidate markers suitable for the task-at-hand must be identified from among thousands of proteins. SAGE-identified biomarkers hold promise for recognition of the stages of neoplasia by proteomic patterns. Optical contrast agents bound to these membrane-bound protein biomarkers will serve as a complement to histopathology, thus allowing more effective determination of tumor borders and non-invasive observation of response to treatment at a molecular level. We present fifty-six cell-surface gene products differentially expressed during progression of cervical intraepithelial neoplasia. Differential gene expression of these biomarkers will allow individualized selection of therapeutic combinations that best target the entire disease-protein system and advance understanding of carcinogenesis.
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Biomarker descriptions
======================

ACTR3 ARP3 actin-related protein 3 homolog (yeast). The protein encoded by this gene is known to be a major constituent of the ARP2/3 complex ([@b151-bmi-2007-447]). This complex is located at the cell surface and is essential to cell shape and motility through lamellipodial actin assembly and protrusion ([@b85-bmi-2007-447]).

Structure information: [1K8K]{.ul} Crystal Structure of Arp2/3 Complex ([@b121-bmi-2007-447]).

*ANPEP* alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150). Human aminopeptidase N is a receptor for one strain of human coronavirus ([@b160-bmi-2007-447]; [@b16-bmi-2007-447]). The large extra-cellular carboxyterminal domain contains a pentapeptide consensus sequence characteristic of members of the zinc-binding metalloproteinase super-family. Defects in this gene appear to be a cause of various types of leukemia or lymphoma.

*BST2* bone marrow stromal cell antigen 2. Bone marrow stromal cells are involved in the growth and development of B-cells and this protein may play a role in pre-B-cell growth ([@b63-bmi-2007-447]).

*C3orf28* chromosome 3 open reading frame 28 (HGTD-P). When overexpressed, HGTD-P induces cell death via mitochondrial apoptotic cascades ([@b76-bmi-2007-447]; [@b71-bmi-2007-447]).

*C14orf101* chromosome 14 open reading frame 101. Integral to membrane (Ensembl-Gene ENSG00000070269: inferred from electronic annotation).

*CACNA2D3* calcium channel, voltage-dependent, alpha 2/delta 3 subunit. This gene encodes a member of the alpha-2/delta subunit family, a protein in the voltage-dependent calcium channel complex ([@b51-bmi-2007-447]).

*CD74 CD74* molecule, major histocompatibility complex MHC, class II invariant chain. CD74 is a nonpolymorphic type II integral membrane protein with an N-terminal cytoplasmic tail. CD74 is a regulated intra-membrane proteolysis RIP protein and its roles as a chaperone and as a signalling molecule are tightly regulated ([@b139-bmi-2007-447]; [@b10-bmi-2007-447]). In addition, CD74 is an accessory signalling molecule during T-cell responses through interactions with CD44 ([@b96-bmi-2007-447]). Providing further evidence for its role in signal transduction pathways, CD74 is now known to be a high affinity binding protein for the proinflammatory cytokine, macrophage migration-inhibitory factor (MIF); MIF binds to the extracellular domain of CD74 ([@b79-bmi-2007-447]). MIF is also implicated in tumour cell growth and angiogenesis ([@b97-bmi-2007-447]).

Structure information: [1IIE]{.ul} (75 amino acids; 296 in CD74) HLA-DR antigens associated invariant chain ([@b66-bmi-2007-447]). [1MIF]{.ul} Macrophase migration inhibitory factor (MIF) ([@b141-bmi-2007-447]).

*CEACAM5* carcinoembryonic antigen-related cell adhesion molecule 5. CEACAM1 interacts heterophilically with the CEA (CEACAM5) protein. Because CEA is expressed on a wide range of carcinomas and commonly used as tumour marker, a novel role for the CEA protein enabling the escape of tumour cells from NK-mediated killing is now apparent ([@b138-bmi-2007-447]).

Structure information: [1E07]{.ul} Model of human carcinoembryonic antigen by homology modelling and curve-fitting to experimental solution scattering data ([@b14-bmi-2007-447]). [2GK2]{.ul} Crystal structure of the N-terminal domain of human CEACAM1 ([@b35-bmi-2007-447]). Using the BLOSUM62 comparison matrix, CEACAM1 (468 residues) has 74.3% identity to CEACAM5 (702 residues) in 412 residue overlap.

*CLCA4* chloride channel, calcium activated, family member 4. The protein encoded by this gene belongs to the calcium sensitive chloride conductance protein family; the exact function is not known ([@b2-bmi-2007-447]; [@b118-bmi-2007-447]).

*CLIC6* chloride intracellular channel 6. This gene encodes a member of the chloride intracellular channel family of proteins.

Structure information: [2D2Z]{.ul} Crystal structure of soluble form of CLIC4 ([@b80-bmi-2007-447]).

*DSG1* desmoglein 1. Desmoglein 1 is a calcium-binding trans-membrane glycoprotein component of desmosomes in vertebrate epithelial cells ([@b153-bmi-2007-447]; [@b50-bmi-2007-447]).

*EMP1* epithelial membrane protein 1. A well-known tumour-associated gene and a member of a novel family of genes encoding membrane glycoproteins ([@b11-bmi-2007-447]; [@b129-bmi-2007-447]), EMP1 is a biomarker of gefitinib resistance ([@b65-bmi-2007-447]). Gefitinib is a small-molecule inhibitor that competes for the ATP-binding site on EGF receptor (EGFR) and has been approved for patients with advanced lung cancers.

Structure information: [1EBP]{.ul} Complex between the extracellular domain of erythropoietin (EPO) receptor \[EBP\] and an agonist peptide \[EMP1\] ([@b81-bmi-2007-447]).

*EPHA1* EPH receptor A1. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system ([@b37-bmi-2007-447]). Structure information: [2GSF]{.ul} The Human Epha3 Receptor Tyrosine Kinase and Juxtamembrane Region ([@b23-bmi-2007-447]). [1MQB]{.ul} Crystal Structure of Ephrin A2 (ephA2) Receptor Protein Kinase ([@b98-bmi-2007-447]).

*FADS2* fatty acid desaturase 2. FADS family members are considered fusion products composed of an N-terminal cytochrome b5-like domain and a C-terminal multiple membrane-spanning desaturase portion, both of which are characterized by conserved histidine motifs ([@b89-bmi-2007-447]; [@b128-bmi-2007-447]).

*FCGBP* Fc fragment of IgG binding protein ([@b73-bmi-2007-447]; [@b53-bmi-2007-447]; [@b100-bmi-2007-447]). The encoded protein is made up of 3004 amino acid residues.

*FER1L4* fer-1-like 4 (*C. elegans*). Novel human gene OTOF is the second member of a mammalian gene family related to *C. elegans* fer-1. It encodes a predicted cytosolic protein with a single carboxyterminal trans-membrane domain. The sequence homologies and predicted structure of otoferlin, the protein encoded by OTOF, suggest its involvement in vesicle membrane fusion ([@b159-bmi-2007-447]).

*FGFR2* fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome). FGFR2 is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform ([@b7-bmi-2007-447]). The extra-cellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation.

Structure information: [1OEC]{.ul} FGFR2 kinase domain (Ceska et al. 2004).

*FLJ32028* transmembrane protein 154. Hypothetical protein LOC201799. Integral to membrane (Ensembl-Gene ENSG00000170006: inferred from electronic annotation).

*FXYD3* FXYD domain containing ion transport regulator 3. FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. Trans-membrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane ([@b21-bmi-2007-447]; [@b39-bmi-2007-447]). The protein encoded by this gene may function as a chloride channel or as a chloride channel regulator.

*GAS1* growth arrest-specific 1. GAS1 plays a role in growth suppression and blocks entry to S phase and prevents cycling of normal and transformed cells ([@b24-bmi-2007-447]). Gas1 is a putative tumour suppressor gene ([@b34-bmi-2007-447]).

*GJB2* gap junction protein, beta 2, 26kDa. The cytoplasmic domains of the connexion 26 gap junction surface, imaged at sub-molecular resolution, form a hexameric pore protruding from the membrane bilayer ([@b92-bmi-2007-447]).

*GPC4* glypican 4. Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. These proteins may play a role in the control of cell division and growth regulation ([@b12-bmi-2007-447]).

*HLA-B* major histocompatibility complex, class I, B. HLA-B belongs to the HLA class I heavy chain paralogues. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen and are expressed in nearly all cells. The heavy chain is anchored in the membrane.

Structure information: [1HSA]{.ul} The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC ([@b86-bmi-2007-447]).

*HLA-DRA* major histocompatibility complex, class II, DR alpha. It is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane, and it plays a central role in the immune system.

Structure information: [1AQD]{.ul} HLA-DR1 (DRA, DRB1 0101) Human class II histocompatibility protein (extracellular domain) complexed with endogenous ([@b93-bmi-2007-447]). [1YMM]{.ul} TCR/HLA-DR2b/MBP-peptide complex ([@b47-bmi-2007-447]).

*IL1R1* interleukin 1 receptor, type I. This protein is a receptor for interleukin alpha, interleukin beta, and interleukin 1 receptor, type I ([@b26-bmi-2007-447]; [@b91-bmi-2007-447]). It is an important mediator involved in many cytokine induced immune and inflammatory responses ([@b13-bmi-2007-447]). Structure information: [1IRA]{.ul} Complex of the interleukin-1 receptor with the interleukin-1 receptor antagonist (IL1RA) ([@b130-bmi-2007-447]).

*ITR G* protein-coupled receptor 180. This protein is produced predominantly in vascular smooth muscle cells and may play an important role in the regulation of vascular remodelling ([@b62-bmi-2007-447]).

*LOC644410* FCGR1C Fc fragment of IgG, high affinity Ic, receptor (CD64). Only Fc gamma RI has high affinity for ligand and has a unique third extra-cellular domain (EC3). Three genes for human Fc gamma RI (A, B, and C) have been characterised; although they are remarkably similar, genes B and C are notably different from A ([@b33-bmi-2007-447]).

Structure information: [1E4J]{.ul} Crystal structure of the soluble human FC-gamma receptor III ([@b137-bmi-2007-447]).

*LY6E* lymphocyte antigen 6 complex, locus E. Acute promyelocytic leukemia APL is a human malignancy that responds to differentiation therapy with all-trans-retinoic acid ATRA ([@b58-bmi-2007-447]). ATRA induces the expression of a novel human gene, RIG-E ([@b88-bmi-2007-447]). The amino acid composition of its product indicates that it is membrane-associated and has high homology to the murine LY-6 proteins and weak homology with a number of human growth factor receptors.

*MGC45438* hypothetical protein MGC45438. Type I membrane protein (LOCATE).

*LYNX1* Ly6/neurotoxin 1. Ly-6/neurotoxin gene family members are lymphocyte antigens that attach to the cell surface by a glycosylphosphatidylinositol anchor and have a unique structure displayed 8--10 conserved cysteine residues ([@b144-bmi-2007-447]). Functional analysis indicates that LYNX1 can enhance nicotinic acetylcholine receptor function in the presence of acetylcholine ([@b4-bmi-2007-447]). It is a new marker for human breast cancer ([@b77-bmi-2007-447]).

*LYPD3* LY6/PLAUR domain containing 3 (C4.4A). This protein is known to be a structural homologue of the urokinase-type plasminogen activator receptor (uPAR) but little is known about its function ([@b52-bmi-2007-447]).

*MAL* mal, T-cell differentiation protein. The protein encoded by this gene is a highly hydrophobic integral membrane protein belonging to the MAL family of proteolipids ([@b82-bmi-2007-447]; [@b30-bmi-2007-447]).

*MUC1* mucin 1, cell-surface associated. This gene is a member of the mucin family and encodes a membrane bound, glycosylated phosphoprotein. The protein is anchored to the apical surface of many epithelia by a trans-membrane domain, with the degree of glycosylation varying with cell type. The protein serves a protective function by binding to pathogens and also functions in a cell signalling capacity ([@b115-bmi-2007-447]). Over-expression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas ([@b109-bmi-2007-447]; [@b110-bmi-2007-447]).

Structure information: [2ACM]{.ul} Solution structure of the SEA domain of human mucin 1 (MUC1) ([@b84-bmi-2007-447]).

*MUC16* mucin 16 (CA125), cell surface associated. CA125 protein core is composed of a short cytoplasmic tail, a trans-membrane domain, and an extraordinarily large glycosylated extracellular structure. The extracellular domain encompasses an interactive disulfide bridged cysteine-loop and the site of OC125 and M11 binding ([@b99-bmi-2007-447]). It is known to be a marker in several cancers, including ovarian ([@b163-bmi-2007-447]), renal ([@b6-bmi-2007-447]), and lung ([@b106-bmi-2007-447]).

*NIP* hypothetical protein FLJ32334 (DUOXA1). Multi-pass membrane protein (Ensembl-Gene ENSG00000140254: inferred from electronic annotation).

*ODZ2* odz, odd Oz/ten-m homolog 2 (Drosophila). This protein is membrane-bound transcription regulator (Baqutti et al. 2003).

*PERP* PERP, TP53 apoptosis effector. This tetraspan protein localizes to the plasma membrane, rather than to mitochondria, and may stimulate apoptosis ([@b61-bmi-2007-447]).

*PIGR* polymeric immunoglobulin receptor. PIGR mediates trans-cellular transport of polymeric immunoglobulin molecules. The receptor has 5 units with homology to the variable (V) units of immunoglobulins and a trans-membrane region, which also has some homology to certain immunoglobulin variable regions.

Structure information: [1XED]{.ul} Crystal Structure of a Ligand-Binding Domain of the Human Polymeric Ig Receptor, pIgR ([@b48-bmi-2007-447]).

*PROM1* prominin 1. The PROM1 gene codes for a pentaspan trans-membrane glycoprotein. The PROM1 antigen appears to belong to a new molecular family of 5-TM proteins which include an extra-cellular N-terminus, two short intracellular loops, two large extra-cellular loops and an intra-cellular C-terminus. PROM1 has been shown to be expressed on haemangioblasts and neural stem cells as well as on developing epithelium ([@b57-bmi-2007-447]; [@b38-bmi-2007-447]). No natural ligand has yet been demonstrated for the PROM1 molecule ([@b158-bmi-2007-447]).

*PSCA* prostate stem cell antigen. This gene encodes a glycosylphosphatidylinositol-anchored cell membrane glycoprotein and a target for immunotherapy ([@b114-bmi-2007-447]; [@b152-bmi-2007-447]).

*PTP4A2* protein tyrosine phosphatase type IVA, member 2. The protein encoded by this gene belongs to a small class of prenylated protein tyrosine phosphatases (PTPs). PTPs are cell signalling molecules that play regulatory roles in a variety of cellular processes ([@b8-bmi-2007-447]; [@b123-bmi-2007-447]). Overexpression of this gene in mammalian cells conferred a transformed phenotype, which suggested its role in tumourigenesis ([@b17-bmi-2007-447]).

Structure information: [1XM2]{.ul} Crystal structure of Human PRL-1 ([@b67-bmi-2007-447]).

*PTP4A3* protein tyrosine phosphatase type IVA, member 3. Over-expression of this PTP gene in mammalian cells was reported to inhibit angiotensin-II induced cell calcium mobilization and promote cell growth ([@b90-bmi-2007-447]).

Structure information: *1V3A* Structure of human PRL-3, the phosphatase associated with cancer metastasis ([@b72-bmi-2007-447]).

*PTPNS1* SIRPA signal-regulatory protein alpha. Signal-regulatory-protein (SIRP) family members are receptor-type transmembrane glycoproteins known to be involved in the negative regulation of receptor tyrosine kinase-coupled signalling processes ([@b69-bmi-2007-447]). CD47 has been known to be a ligand for this PTPNS1 ([@b140-bmi-2007-447]).

Structure information: [2D9C]{.ul} Solution structure of the first ig-like domain of signal-regulatory protein beta-1 (SIRP-beta-1) ([@b95-bmi-2007-447]).

*RHCG* Rh family, C glycoprotein. RhCG facilitates ammonium movement across the plasma membrane ([@b165-bmi-2007-447]).

*SLC30A1* solute carrier family 30 (zinc transporter), member 1. Transports zinc out of cells; its absence accounts for increased sensitivity of mutant cells to zinc toxicity ([@b102-bmi-2007-447]).

*SLC39A3* solute carrier family 39 (zinc transporter), member 3. These eight-transmembrane domain proteins are part of the Zrt/Irt-like protein (ZIP) super-family of metal ion transporters and contain a conserved 12-amino acid signature sequence within the fourth transmembrane domain ([@b41-bmi-2007-447], [@b42-bmi-2007-447]; [@b29-bmi-2007-447]).

*SRD5A2L* steroid 5 alpha-reductase 2-like; 3-oxo-5-alpha-steroid 4 dehydrogenase activity.

*STRA6* stimulated by retinoic acid gene 6 homolog (mouse). Stra6 codes for a very hydrophobic membrane protein of a new type, which does not display similarities with previously characterized integral membrane proteins ([@b15-bmi-2007-447]).

*TACSTD2* tumour-associated calcium signal transducer 2. This gene encodes a carcinoma-associated antigen, defined by the monoclonal antibody GA733. TACSTD2 transduces an intra-cellular calcium signal and acts as a cell surface receptor ([@b117-bmi-2007-447]).

*TFF3* trefoil factor 3. Trefoil family members are stable, secretory proteins having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulphides. VANGL, Van Gogh-like protein 1, is phosphorylated in response to Intestinal Trefoil Factor (ITF) stimulation. Vangl1 protein acts as a downstream effector of ITF/TFF3 signalling and regulates wound healing of the intestinal epithelium ([@b68-bmi-2007-447]). TFF3 is commonly expressed in hepatocellular carcinoma and its expression correlates with tumour grade ([@b70-bmi-2007-447]).

Structure information: [1E9T]{.ul} High resolution solution structure of human intestinal trefoil factor ([@b78-bmi-2007-447]; [@b94-bmi-2007-447]).

*TGFA* transforming growth factor, alpha. TGF-alpha shows about 40% sequence homology with epidermal growth factor (EGF) and competes with EGF for binding to the EGF receptor ([@b75-bmi-2007-447]; [@b155-bmi-2007-447]).

Structure information: [1MOX]{.ul} Crystal Structure of Human Epidermal Growth Factor Receptor (residues 1-501) in complex with TGF-alpha ([@b43-bmi-2007-447]). [2TGF]{.ul} The solution structure of human transforming growth factor alpha (Harvey et al. 2001).

*TMEM45B* transmembrane protein 45B. Integral to membrane (Ensembl-Gene ENSG0000051715: inferred from electronic annotation).

*TMEM54* transmembrane protein 54. Integral to membrane (Ensembl-Gene ENSG00000121900: inferred from electronic annotation).

*TMPRSS2* transmembrane protease, serine 2. This gene was demonstrated to be up-regulated by androgenic hormones in prostate cancer cells and down-regulated in androgen-independent prostate cancer tissue ([@b1-bmi-2007-447]). The protease domain of this protein is thought to be cleaved and secreted into cell media after autocleavage.

The encoded protein contains a type II transmembrane domain, a receptor class A domain, a scavenger receptor cysteine-rich domain and a protease domain.

Structure information: [1Z8G]{.ul} Crystal structure of the extracellular region of the transmembrane serine protease hepsin with covalently bound preferred substrate ([@b56-bmi-2007-447]).

*TMPRSS11B* transmembrane protease, serine 11B. Integral to membrane (Ensembl-Gene ENSG00000185873: inferred from electronic annotation).

Structure information: [1Z8G]{.ul} (see TMPRSS2)

*TSPAN1* tetraspanin 1. Most members of the trans-membrane 4 superfamily are cell-surface proteins characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility ([@b143-bmi-2007-447]). Tetraspanin protein, C4.8, identical to NET-1, has been implicated in cervical carcinogenesis ([@b156-bmi-2007-447]).

*UPK1*[A]{.ul} uroplakin 1A. The tetraspanin protein encoded by this gene is found in the asymmetrical unit membrane (AUM) where it can complex with other trans-membrane 4 superfamily proteins ([@b164-bmi-2007-447]). It may play a role in regulating membrane permeability of superficial umbrella cells or in stabilizing the apical membrane through AUM/cytoskeletal interactions ([@b116-bmi-2007-447]).

###### 

Highly expressed genes with membrane-bound gene products up-regulated in cervical dysplasia stages CINI and CINIII. Up-regulated gene expression, from normal, ≥2-fold.

  Tag sequence        Number of tags in disease libraries[\*](#tfn1-bmi-2007-447){ref-type="table-fn"}   Number of tags in normal libraries   Gene                                                       Fold increase from normal   RefSeq accession number
  ------------------- ---------------------------------------------------------------------------------- ------------------------------------ ---------------------------------------------------------- --------------------------- -------------------------
  **CINIII**                                                                                                                                                                                                                         
  GACCCAAGATAAAAGAA   704                                                                                16                                   PIGR                                                       22.4                        NM_002644
  ATCCCCCTGGGCATCGG   52                                                                                 2                                    SLC39A3                                                    13.2                        NM_144564
  ACTCAGACCAGGTCCCA   94                                                                                 4                                    STRA6                                                      11.4                        NM_022369
  ACACAGTATTCGCTCTT   44                                                                                 2                                    ITR                                                        11.2                        NM_180989
  TTACTTCCCCACCCCTA   84                                                                                 4                                    FADS2                                                      10.7                        NM_004265
  GGAACTGTGAAGAGGCA   230                                                                                12                                   TSPAN1                                                     9.7                         NM_005727
  GCACCTGTCGCCCAGTG   36                                                                                 2                                    ANPEP                                                      9.2                         NM_001150
  CCTGATCTGCGGTGTCC   308                                                                                18                                   MUC16                                                      8.7                         NM_024690
  CGTTTTCTGATAACTCA   68                                                                                 4                                    PTP4A2                                                     8.6                         XM_001132367
  CAAATAAATTATGCGAT   98                                                                                 6                                    TMPRSS2                                                    8.3                         NM_005656
  TGCTCCTACCCTGCTCT   2022                                                                               190                                  FCGBP                                                      5.4                         XM_001131379
  GCAGTGCCACTCAAGAA   726                                                                                68                                   SRD5A2L                                                    5.4                         NM_024592
  CCTGGGAAGTGTTGTGG   730                                                                                98                                   MUC1                                                       3.8                         NM_001044391
  AATATTTATATTGTATG   1880                                                                               400                                  CEACAM5                                                    2.4                         NM_004363
  GTTCACATTAGAATAAA   3424                                                                               762                                  CD74                                                       2.3                         NM_001025158
  GGGCATCTCTTGTGTAC   1602                                                                               350                                  HLA-DRA                                                    2.3                         NM_019111
  TGCTGCCTGTTGTTATG   826                                                                                192                                  BST2                                                       2.2                         NM_004335
  CTGACCTGTGTTTCCTC   596                                                                                144                                  HLA-B                                                      2.1                         NM_005514
  GCAGGGCCTCATCTCAC   1950                                                                               484                                  FXYD3                                                      2.0                         NM_005971
                                                                                                                                                                                                                                     
  **CINI**                                                                                                                                                                                                                           
  GCACCTGTCGCCCAGTG   42                                                                                 2                                    ANPEP                                                      36.5                        NM_001150
  ATGTTAATAAAATAGGC   66                                                                                 4                                    GPC4                                                       28.7                        NM_001448
  ATAAATGATTAGACTAC   32                                                                                 2                                    CLIC6                                                      27.8                        NM_053277
  GGCCAAGAACTTTCACT   28                                                                                 2                                    C14orf101                                                  24.3                        NM_017799
  GACCCAAGATAAAAGAA   262                                                                                16                                   PIGR                                                       23.0                        NM_002644
  TAGGTCAGGACCTTGGC   26                                                                                 2                                    PTP4A3                                                     22.6                        NM_032611
  GTATATAACTCTTAAAG   24                                                                                 2                                    LOC644410[\*\*](#tfn2-bmi-2007-447){ref-type="table-fn"}   20.8                        XM_001133198
  CCAGCTGCCTGGAGGAG   22                                                                                 2                                    MGC45438                                                   19.1                        NM_152459
  ATAAAAATTAGGGGGAT   22                                                                                 2                                    SLC30A1                                                    19.1                        NM_021194
  TGAGCTACCCCAGAGTC   20                                                                                 2                                    FER1L4                                                     17.4                        NR_001442
  TACATCAGTAAAGAGTT   374                                                                                42                                   GAS1                                                       12.5                        NM_002048
  CATCACGGATCAATAGA   330                                                                                64                                   IL1R1                                                      7.2                         NM_000877
  CCTGGGAAGTGTTGTGG   334                                                                                98                                   MUC1                                                       4.1                         NM_001044391
  TGCAGATTGCAGTTCTG   366                                                                                132                                  PROM1                                                      3.9                         NM_006017
  CACTTCAAGGGCAGCCT   238                                                                                102                                  LY6E                                                       3.3                         NM_002346
  GTTCACATTAGAATAAA   1660                                                                               762                                  CD74                                                       3.1                         NM_001025158
  GGGCATCTCTTGTGTAC   734                                                                                350                                  HLA-DRA                                                    3.0                         NM_019111
  TGCTCCTACCCTGCTCT   402                                                                                190                                  FCGBP                                                      3.0                         XM_001131379
  CTGACCTGTGTTTCCTC   256                                                                                144                                  HLA-B                                                      2.5                         NM_005514

GEO Series Accession Numbers GSE6252. 1,101,702 total longSAGE tags in four normal libraries, GEO Alias N3, N1, N2, N4; 2,165,777 total longSAGE tags in six CINIII libraries, GEO Alias C1, C3, C2, C4, C5, C6; 785,642 total longSAGE tags in three CINI libraries, GEO Alias M1, M2, M3.

Mapping unable to be confirmed through ENSEMBL or BLAT.

###### 

Highly expressed genes with membrane-bound gene products up-regulated in normal cervical tissue. Up-regulated gene expression, from CINI and/or CINIII, ≥2-fold.

  Tag sequence        Number of tags in disease libraries[\*](#tfn3-bmi-2007-447){ref-type="table-fn"}   Number of tags in normal libraries   Gene        Fold increase from disease state   RefSeq accession number
  ------------------- ---------------------------------------------------------------------------------- ------------------------------------ ----------- ---------------------------------- -------------------------
  **CINIII**                                                                                                                                                                                 
  AGACTTGGCATACACAC   2                                                                                  30                                   ACTR3       29.5                               NM_005721
  TAACTGGCCTTACGATG   6                                                                                  54                                   DSG1        17.7                               NM_001942
  AGAGGGATGAGGCAACC   2                                                                                  18                                   GJB2        17.7                               NM_004004
  AGTCCTGGAGGAGGAGA   2                                                                                  18                                   PTPNS1      17.7                               NM_001040022
  GCTGACAGTCCCAAGTC   2                                                                                  16                                   NIP         15.7                               NM_144565
  ACAGTCACCACGAGGAG   2                                                                                  16                                   ODZ2        15.7                               XM_047995
  AGAGTTCTGTCACGGTC   8                                                                                  62                                   UPK1A       15.2                               NM_007000
  CAGTATTTTAAATAATT   2                                                                                  12                                   FLJ32028    11.8                               NM_152680
  ATAATCACCCTTCATCA   2                                                                                  12                                   CACNA2D3    11.8                               NM_018398
  TGGTGGCTGCTTTTCCC   2                                                                                  10                                   TMEM54      9.8                                NM_033504
  CCAGCGCCAACCAGTCA   272                                                                                482                                  LYPD3       3.5                                NM_014400
  GTTTCCAAAAAATGGTA   350                                                                                438                                  GJB2        2.5                                NM_004004
  GTGGAAGACGATAACCC   5664                                                                               7334                                 MAL         2.5                                NM_002371
  GCCCAGCATTCTCCACC   856                                                                                832                                  PSCA        1.9                                NM_005672
  CTTGATTCCCACGCTAC   236                                                                                230                                  QSCN6       1.9                                NM_002826
  GTTATTGAGGGCAAGAA   196                                                                                194                                  C3orf28     1.9                                NM_014367
                                                                                                                                                                                             
  **CINI**                                                                                                                                                                                   
  CAATCTTGCAGTGAAGA   6                                                                                  226                                  TMPRSS11B   26.9                               NM_182502
  TCAGAATGATTCTGGTG   22                                                                                 346                                              11.2                               
  AGAGTTCTGTCACGGTC   2                                                                                  62                                   UPK1A       22.1                               NM_007000
  GCATAACAACTCCCCAA   4                                                                                  60                                   EMP1        10.7                               NM_001423
  TAATTTGCATTACTCTG   366                                                                                2036                                             4.0                                
  GATCCAGATGCCTGAGG   4                                                                                  74                                   LYNX1       13.2                               NM_023946
  CCAGCGCCAACCAGTCA   28                                                                                 482                                  LYPD3       12.3                               NM_014400
  GATGAATCCGGGGTATG   4                                                                                  68                                   TMEM45B     12.1                               NM_138788
  TATATTTTTAAATGTTC   2                                                                                  30                                   TGFA        10.7                               NM_003236
  TAACCCCTCTCACCTGC   2                                                                                  28                                   FGFR2       10.0                               NM_022970
  GGGACTAAAACTCACCC   2                                                                                  28                                   MAL         10.0                               NM_002371
  GGAGGGAGCTGAGGGGT   2                                                                                  28                                   EPHA1       10.0                               NM_005232
  GCCCAGCATTCTCCACC   82                                                                                 832                                  PSCA        7.2                                NM_005672
  GTTATTGAGGGCAAGAA   30                                                                                 194                                  C3orf28     4.6                                NM_014367
  GTTTCCAAAAAATGGTA   70                                                                                 438                                  GJB2        4.5                                NM_004004
  GCTTCCTCGGTACCCTT   252                                                                                1590                                 RHCG        4.5                                NM_016321
  CCACAGGAGAATTCGGG   952                                                                                5624                                 PERP        4.2                                NM_022121
  GATATGTAAAAACTGTC   38                                                                                 194                                  CLCA4       3.6                                NM_012128
  GCCTACCCGAGGAGAAG   132                                                                                616                                  TACSTD2     3.3                                NM_002353

GEO Series Accession Number GSE6252. 1,101,702 total longSAGE tags in four normal libraries, GEO Alias N3, N1, N2, N4; 2,165,777 total longSAGE tags in six CINIII libraries, GEO Alias C1, C3, C2, C4, C5, C6; 785,642 total longSAGE tags in three CINI libraries, GEO Alias M1, M2, M3.
